GMAB Stock Analysis: Genmab | CO
Biotechnology | CO, Denmark | Market Cap: 113.732m DKK | 12M Return: 27.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 227M
EPS Trend: 76.7%
Qual. Beats: 0
Rev. Trend: -64.2%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Genmab A/S is a Danish biotechnology company founded in 1998 and headquartered in Copenhagen that develops antibody-based therapeutics, primarily for cancer and other serious diseases. Its commercial portfolio includes directly marketed products such as EPKINLY/TEPKINLY for relapsed/refractory B-cell lymphomas and Tivdak for recurrent cervical cancer, alongside royalty-generating products developed by partners, including DARZALEX, RYBREVANT, TECVAYLI, TALVEY, Kesimpta, and TEPEZZA. The company maintains a broad pipeline of antibody and antibody-drug conjugate candidates targeting hematologic malignancies, solid tumors, and other indications such as multiple system atrophy, sickle cell disease, and hemophilia A. Genmab operates a hybrid business model common among large-cap biotechs, combining direct commercialization of select assets with collaboration and royalty agreements with major pharmaceutical companies including AbbVie, Pfizer, Johnson & Johnson, Bristol Myers Squibb, BioNTech, and Novo Nordisk.
- DARZALEX royalties from Johnson & Johnson underpin core revenue
- EPKINLY launches accelerate in DLBCL and follicular lymphoma
- Acasunlimab and Rina-S pipeline data unlock key catalysts
| Net Income: 821.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -89.29 > 1.0 |
| NWC/Revenue: 14.80% < 20% (prev 18.10%; Δ -3.29% < -1%) |
| CFO/TA 0.07 > 3% & CFO 904.1m > Net Income 821.1m |
| Net Debt (3.97b) to EBITDA (1.41b): 2.82 < 3 |
| Current Ratio: 2.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.9m) vs 12m ago -0.12% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 99.35% > 50% (prev 275.3%; Δ -175.9% > 0%) |
| Interest Coverage Ratio: 7.97 > 6 (EBIT TTM 1.33b / Interest Expense TTM 166.5m) |
| A: 0.11 (Total Current Assets 2.57b - Total Current Liabilities 1.18b) / Total Assets 12.4b |
| B: 0.33 (Retained Earnings 4.09b / Total Assets 12.4b) |
| C: 0.14 (EBIT TTM 1.33b / Avg Total Assets 9.47b) |
| D: 0.85 (Book Value of Equity 5.68b / Total Liabilities 6.69b) |
| Altman-Z'' = 3.65 = AA |
| DSRI: 2.48 (Receivables 1.03b/799.0m, Revenue 9.41b/18.1b) |
| GMI: 0.98 (GM 95.35% / 97.22%) |
| AQI: 2.23 (AQ_t 0.77 / AQ_t-1 0.35) |
| SGI: 0.52 (Revenue 9.41b / 18.1b) |
| TATA: -0.01 (NI 821.1m - CFO 904.1m) / TA 12.4b) |
| Beneish M = -1.44 (Cap -4..+1) = D |
As of July 28, 2026, the stock is trading at DKK 1908.00 with a total of 114,942 shares traded. Over the past week, the price has changed by +3.30%, over one month by +11.03%, over three months by +11.78% and over the past year by +27.41%.
Current recommended Stop Loss: 1837.80 (which is 3.7% or 1.3 ATR below the current price).
Genmab has no consensus analysts rating.
P/E Trailing = 21.4311
P/E Forward = 16.5289
P/S = 29.1545
P/B = 3.033
P/EG = 1.8649
Revenue TTM = 9.41b DKK
EBIT TTM = 1.33b DKK
EBITDA TTM = 1.41b DKK
Long Term Debt = 4.93b DKK (from longTermDebt, last quarter)
Short Term Debt = 292.7m DKK (from shortTermDebt, last quarter)
Debt = 5.49b DKK (from shortLongTermDebtTotal, last quarter) + Leases 143.0m
Net Debt = 3.97b DKK (calculated: Debt 5.49b - CCE 1.52b)
Enterprise Value = 118b DKK (114b + Debt 5.49b - CCE 1.52b)
Interest Coverage Ratio = 7.97 (Ebit TTM 1.33b / Interest Expense TTM 166.5m)
EV/FCF = 134.7x (Enterprise Value 118b / FCF TTM 873.9m)
FCF Yield = 0.74% (FCF TTM 873.9m / Enterprise Value 118b)
FCF Margin = 9.28% (FCF TTM 873.9m / Revenue TTM 9.41b)
Net Margin = 8.72% (Net Income TTM 821.1m / Revenue TTM 9.41b)
Gross Margin = unknown ((Revenue TTM 9.41b - Cost of Revenue TTM 261.5m) / Revenue TTM)
Tobins Q-Ratio = 9.52 (Enterprise Value 118b / Total Assets 12.4b)
Interest Expense / Debt = 3.03% (Interest Expense 166.5m / Debt 5.49b)
Taxrate = 20.61% (213.1m / 1.03b)
NOPAT = 1.05b (EBIT 1.33b * (1 - 20.61%))
Current Ratio = 2.18 (Total Current Assets 2.57b / Total Current Liabilities 1.18b)
Debt / Equity = 0.97 (Debt 5.49b / totalStockholderEquity, last quarter 5.68b)
Debt / EBITDA = 2.82 (Net Debt 3.97b / EBITDA 1.41b)
Debt / FCF = 4.55 (Net Debt 3.97b / FCF TTM 873.9m)
Total Stockholder Equity = 5.64b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.67% (Net Income 821.1m / Total Assets 12.4b)
RoE = 14.55% (Net Income TTM 821.1m / Total Stockholder Equity 5.64b)
RoCE = 12.54% (EBIT 1.33b / Capital Employed (Equity 5.64b + L.T.Debt 4.93b))
RoIC = 9.57% (NOPAT 1.05b / Invested Capital 11.0b)
WACC = 7.29% (E(114b)/V(119b) * Re(7.53%) + D(5.49b)/V(119b) * Rd(3.03%) * (1-Tc(0.21)))
Discount Rate = 7.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -32.10 | Cagr: -1.56%
[DCF] Terminal Value 73.10% ; FCFF base≈3.06b ; Y1≈2.69b ; Y5≈2.17b
[DCF] Fair Price = 502.6 (EV 34.8b - Net Debt 3.97b = Equity 30.9b / Shares 61.4m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 76.71 | EPS CAGR: 29.03% | SUE: 0.02 | # QB: 0
Revenue Correlation: -64.20 | Revenue CAGR: -17.45% | SUE: -0.68 | # QB: 0
EPS current Quarter (2026-06-30): EPS=23.35 | Chg30d=+6.24% | Revisions=+17% | Analysts=5
EPS next Quarter (2026-09-30): EPS=23.44 | Chg30d=+14.11% | Revisions=-17% | Analysts=5
EPS current Year (2026-12-31): EPS=75.00 | Chg30d=+0.89% | Revisions=+40% | GrowthEPS=-33.0% | GrowthRev=+19.4%
EPS next Year (2027-12-31): EPS=107.64 | Chg30d=+1.74% | Revisions=+40% | GrowthEPS=+43.5% | GrowthRev=+17.7%
[Analyst] Revisions Ratio: +31% (up=7, down=3)